The existing evidence suggests that the role of combination tyrosine kinase/VEGF inhibition plus immune checkpoint inhibition for patients with advanced hepatocellular carcinoma (aHCC) previously untreated with systemic anticancer therapy and patients with previously treated gastric cancer/gastroesophageal junction adenocarcinoma has not yet been fully investigated. Here, VEGFA is linked to gastroesophageal junction adenocarcinoma.